Entering text into the input field will update the search result below

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug. 19, 2022 11:00 AM ETArvinas, Inc. (ARVN) StockPFE, SNYBy: Jonathan Block, SA News Editor8 Comments

Wall Street sign, New York City, USA

mbbirdy

  • Piper Sandler has started coverage of Arvinas (NASDAQ:ARVN) with a buy rating saying that Sanofi's (SNY) recent discontinuation of amcenestrant for breast cancer will benefit the biotech.
  • The firm has a $76 price target (~65% upside based on Thursday's close).

Recommended For You

About ARVN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ARVN--
Arvinas, Inc.